Biopharmaceutical company Trigemina will deliver clinical data on its drug candidate TI-001 for the treatment of chronic migraine at the ongoing 7th Annual Pain Therapeutics Summit East in Boston, Massachusetts.
The presentation will include details regarding how the nasal application of oxytocin guides the distribution of the peptide to the pain-sensing trigeminal nerve for generating a potent, but safe analgesic effect.
Trigemina chief scientist and founder David Yeomans will deliver presentation that will also include data on the efficacy of TI-001 in decreasing pain for chronic migraineurs.
David Yeomans said that the previous studies have shown the release of calcitonin gene-related peptide (CGRP) by the trigeminal nerve neurons is likely critical to the pain experienced in episodic and chronic migraine patients, as well as in a number of other head pain conditions, especially those involving inflammation.
"Fortunately, the increased levels of inflammatory mediators induces an increase in the number of receptors for oxytocin on trigeminal nerve cells, which when oxytocin binds with, reduces pain," Yeomans added.
"Since chronic migraineurs have higher levels of inflammation, they also have more oxytocin receptors, making TI-001 highly effective in reducing their pain."
TI-001, a patented new application of oxytocin, has demonstrated promising results for use as a safe and effective therapy for all forms of chronic and subacute head pain in previous studies.
It is currently being evaluated in TRIG-05, a placebo-controlled, double-blind, randomized-withdrawal and enrollment enriched Phase II clinical study, for efficacy, tolerability and safety in patients with chronic migraine.
